Trial Profile
Bioequivalence of a 2.5 mg Linagliptin / 850 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 850 mg Tablets Administered Together in Healthy Male and Female Volunteers (an Open-label, Randomised, Single-dose, Two-way Crossover, Phase I Trial)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Aug 2014
Price :
$35
*
At a glance
- Drugs Linagliptin/metformin (Primary) ; Linagliptin; Metformin
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 01 May 2014 Results published in the International Journal of Clinical Pharmacology and Therapeutics.
- 22 Apr 2014 Primary endpoint 'Drug-bioavailability' has been met, according to results published in the International Journal of Clinical Pharmacology and Therapeutics.
- 22 Apr 2014 Primary endpoint 'Area-under-the-drug-concentration-time-curve' has been met, according to results published in the International Journal of Clinical Pharmacology and Therapeutics.